Table 3.
Multivariable Cox regression for mortality in liver transplant recipients.
| Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age, years | 1.03 (0.99–1.06) | 0.108 | ||
| Male sex | 0.67 (0.37–1.22) | 0.194 | ||
| Underlying disease | ||||
| Alcoholic | 0.69 (0.36–1.31) | 0.251 | ||
| Viral hepatitis | 1.29 (0.70–2.35) | 0.415 | ||
| Hypertension | 0.75 (0.33–1.68) | 0.479 | ||
| Diabetes | 1.53 (0.84–2.77) | 0.166 | ||
| Cardiovascular disease | 1.31 (0.53–3.28) | 0.561 | ||
| HCC | 1.62 (0.86–3.07) | 0.136 | ||
| High MELD | 3.94 (1.98–7.84) | < 0.001 | 3.42 (1.52–7.69) | 0.003 |
| Donor age, years | 1.04 (1.02–1.06) | 0.001 | 1.03 (1.00–1.05) | 0.033 |
| Donor sex, male | 2.15 (1.06–4.37) | 0.034 | 1.79 (0.88–3.62) | 0.106 |
| Donor BMI, kg/m2 | 1.11 (1.02–1.20) | 0.013 | 1.08 (0.98–1.18) | 0.133 |
| ABO incompatibility | 0.75 (0.23–2.49) | 0.641 | ||
| Living donor | 0.40 (0.22–0.72) | 0.003 | 1.82 (0.75–4.38) | 0.183 |
| Rejection | 1.17 (0.55–2.48) | 0.688 | ||
| Desensitization | ||||
| Rituximab | 0.63 (0.19–2.09) | 0.454 | 0.60 (0.17–2.13) | 0.431 |
| Plasmapheresis | 0.67 (0.20–2.20) | 0.505 | ||
| Surgery time, hr | 1.00 (0.86–1.17) | 0.989 | ||
| Cold ischemia time, hr | 1.08 (0.98–1.18) | 0.105 | ||
| RBC transfusion, pack | 1.05 (1.02–1.07) | < 0.001 | 1.04 (0.99–1.09) | 0.151 |
| Pre-LT HGG | 4.06 (1.75–9.43) | 0.001 | 2.82 (1.10–7.20) | 0.030 |
| Post-LT HGG | 0.90 (0.37–2.18) | 0.810 | ||
Post-LT HGG was assessed at postoperative 1 month. Post-LT HGG and rejection were used as time-varying variables. HGG was defined as a measured IgG level of < 700 mg/dL7.
BMI, body mass index; CI, confidence interval; HCC, hepatocellular carcinoma; HGG, hypogammaglobulinemia; HR, hazard ratio; LT, liver transplantation; MELD, model for end-stage liver disease; RBC, red blood cell.